TABLE 1.
Demographic, clinical, and pathological characteristics of the study cohort (n = 25)
| Variable | Number (%) |
|---|---|
| Age at diagnosis, median | 54 y (range 33-64) |
| Sex | |
| Male | 4 (16%) |
| Female | 21 (84%) |
| Median BMI (kg/m2) | 29.3 (range 17.7-43.8) |
| Past medical history | |
| Hypertension | 11 (44%) |
| Diabetes mellitus | 1 (4%) |
| Depression | 4 (16%) |
| Asthma | 2 (8%) |
| Breast cancer | 1 (4%) |
| Hyperlipidemia | 4 (16%) |
| Hypothyroidism | 2 (8%) |
| Hyperthyroidism | 1 (4%) |
| Li-Fraumeni syndrome | 1 (4%) |
| Ki-67 index >20% | 25 (100%) |
| Maximum SUV (median) | 9.4 (range: 4.5-45) |
| MTV (median) | 47.5 mL (range: 4.9-416.9 mL) |
| TLG (median) | 197 SUVlbm*mL (range: 3.9-2557.9 SUVlbm*mL) |
| Operation performed | |
| Locoregional resection | 10 (40%) |
| Hepatic resection | 7 (28%)a |
| Pulmonary resection | 4 (16%)b |
| Other intra-abdominal resection | 4 (16%)c |
| R status | |
| R0-1 | 12 (48%) |
| R2 | 13 (52%) |
| Adjuvant chemotherapy after reoperation | 6 (24%) |
| Tariquidar, doxorubicin, vincristine, etoposide, mitotane | 1 (4%) |
| Gefitinib, EDP, metyrapone | 1 (4%) |
| EDP, mitotane | 1 (4%) |
| EDP | 1 (4%) |
| AT-101, mitotane | 1 (4%) |
| Mitotane | 1 (4%) |
| Received chemotherapy before resection | 20 (80%) |
| Time-to-recurrence >12 mo | 12 (48%) |
Abbreviations: BMI, body mass index, EDP, etoposide, doxorubicin, cisplatin; MTV, metabolic tumor volume; SUV, standardized uptake value; TLG, total lesion glycolysis.
^
Includes small bowel and colon resections for metastatic disease.
a
Three hepatic resections were performed for single lesions and four hepatic resections for multiple lesions. Five out of seven patients recurred late ( > 12 mo).
b
All pulmonary resections were performed for multiple lesions. Three out of four patients recurred early (<12 mo).
c
Includes small bowel and colon resections for metastatic disease.